FDA-cleared profile

TeraRecon Cardiac.Chambers.MR (1.0.0)

TeraRecon,Inc. · MRI · FDA-cleared (510(k))

Authorized purpose: Provide cardiac-chamber segmentations for trained healthcare professionals reviewing adult cardiac MR to assist diagnosis or treatment planning; the physician makes final patient-management decisions.

Clinical role
Cardiac MR post-processing segmentation aid for chamber delineation and downstream review or planning.
Images and patients
MRI · Cardiac chambers: left-ventricular myocardium and chamber, and right-ventricular chamber for the Cine-ax component; left-ventricular myocardium and chamber for the De-ax component.
Key limitation
Keep in mind: Adult cardiac MR use is labeled; contrast or non-contrast DICOM cardiac MR input and the supported component-specific sequences are required. The physician remains responsible for final management decisions, and exact local sequence/interface compatibility requires confirmation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Provide cardiac-chamber segmentations for trained healthcare professionals reviewing adult cardiac MR to assist diagnosis or treatment planning; the physician makes final patient-management decisions.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Cardiac chambers: left-ventricular myocardium and chamber, and right-ventricular chamber for the Cine-ax component; left-ventricular myocardium and chamber for the De-ax component. Input: Contrast or non-contrast DICOM-compliant cardiovascular MR images from adults. Cine-ax uses 4D multiphase GRE and De-ax uses 3D multi-slice IR single-phase data; the validation cohort used GE, Philips, and Siemens scanners with cardiac gating and breath synchronization.
  • Who uses it?Intended users: Trained healthcare professionals, including physicians experienced in examining and evaluating cardiovascular MR images.
  • What does the software produce?Output: DICOM files containing Cine-ax LV myocardium, LV chamber, and RV chamber segmentations, and De-ax LV myocardium and LV chamber segmentations, for use in DICOM-compliant viewers such as TeraRecon Intuition or PACS.
  • What is its most important limitation?Key limitation: Adult cardiac MR use is labeled; contrast or non-contrast DICOM cardiac MR input and the supported component-specific sequences are required. The physician remains responsible for final management decisions, and exact local sequence/interface compatibility requires confirmation.

Clinical takeaway. Clinical role: Provide cardiac-chamber segmentations for trained healthcare professionals reviewing adult cardiac MR to assist diagnosis or treatment planning; the physician makes final patient-management decisions.

Evidence takeaway. Evidence from the reviewed source record: FDA K241312 reports a retrospective validation cohort of 100 adults split into 50 Cine-ax and 50 De-ax patients, with ground truth reviewed by a board-certified radiologist. Cine-ax mean Dice scores were 0.82 (95% CI 0.81-0.83) for LV myocardium, at least 0.90 (0.89-0.91) for LV chamber, and 0.84 (0.82-0.85) for RV chamber. De-ax mean Dice scores were 0.79 (0.75-0.83) for LV myocardium and 0.88 (0.84-0.92) for LV chamber. The packet reports acceptance criteria were met across stated subgroups.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Provide cardiac-chamber segmentations for trained healthcare professionals reviewing adult cardiac MR to assist diagnosis or treatment planning; the physician makes final patient-management decisions.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Cardiac MR post-processing segmentation aid for chamber delineation and downstream review or planning.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Contrast or non-contrast DICOM-compliant cardiovascular MR images from adults. Cine-ax uses 4D multiphase GRE and De-ax uses 3D multi-slice IR single-phase data; the validation cohort used GE, Philips, and Siemens scanners with cardiac gating and breath synchronization.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
DICOM files containing Cine-ax LV myocardium, LV chamber, and RV chamber segmentations, and De-ax LV myocardium and LV chamber segmentations, for use in DICOM-compliant viewers such as TeraRecon Intuition or PACS.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Adult cardiac MR procedure and post-processing workflow; facility type is not specified in the FDA packet.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Trained healthcare professionals, including physicians experienced in examining and evaluating cardiovascular MR images.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
Adult cardiac MR use is labeled; contrast or non-contrast DICOM cardiac MR input and the supported component-specific sequences are required. The physician remains responsible for final management decisions, and exact local sequence/interface compatibility requires confirmation.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA K241312 reports a retrospective validation cohort of 100 adults split into 50 Cine-ax and 50 De-ax patients, with ground truth reviewed by a board-certified radiologist. Cine-ax mean Dice scores were 0.82 (95% CI 0.81-0.83) for LV myocardium, at least 0.90 (0.89-0.91) for LV chamber, and 0.84 (0.82-0.85) for RV chamber. De-ax mean Dice scores were 0.79 (0.75-0.83) for LV myocardium and 0.88 (0.84-0.92) for LV chamber. The packet reports acceptance criteria were met across stated subgroups.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA K241312 reports a retrospective validation cohort of 100 adults split into 50 Cine-ax and 50 De-ax patients, with ground truth reviewed by a board-certified radiologist. Cine-ax mean Dice scores were 0.82 (95% CI 0.81-0.83) for LV myocardium, at least 0.90 (0.89-0.91) for LV chamber, and 0.84 (0.82-0.85) for RV chamber. De-ax mean Dice scores were 0.79 (0.75-0.83) for LV myocardium and 0.88 (0.84-0.92) for LV chamber. The packet reports acceptance criteria were met across stated subgroups.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

TeraRecon Cardiac.Chambers.MR (1.0.0) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K241312
  • Samplen=100
  • IndependenceIndependence not established

K241312

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241312. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Contrast or non-contrast DICOM-compliant cardiovascular MR images from adults. Cine-ax uses 4D multiphase GRE and De-ax uses 3D multi-slice IR single-phase data; the validation cohort used GE, Philips, and Siemens scanners with cardiac gating and breath synchronization.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K241312: TeraRecon Cardiac.Chambers.MR (1.0.0)

  2. Routing

    Source context, not route validation: Containerized deployment and DICOM-compliant input/output are described; output files may be used by TeraRecon Intuition, PACS, or other DICOM-compliant systems. Exact interface versions and local routing behavior are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K241312: TeraRecon Cardiac.Chambers.MR (1.0.0)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: DICOM files containing Cine-ax LV myocardium, LV chamber, and RV chamber segmentations, and De-ax LV myocardium and LV chamber segmentations, for use in DICOM-compliant viewers such as TeraRecon Intuition or PACS.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K241312: TeraRecon Cardiac.Chambers.MR (1.0.0)

  5. Viewer/worklist/report

    Unresolved route: DICOM files containing Cine-ax LV myocardium, LV chamber, and RV chamber segmentations, and De-ax LV myocardium and LV chamber segmentations, for use in DICOM-compliant viewers such as TeraRecon Intuition or PACS.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K241312: TeraRecon Cardiac.Chambers.MR (1.0.0)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Containerized deployment and DICOM-compliant input/output are described; output files may be used by TeraRecon Intuition, PACS, or other DICOM-compliant systems. Exact interface versions and local routing behavior are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Security
TeraRecon announces it has been recognized as an ISO 27001:2022 certified company, maintaining an information security management system with documented processes for managing sensitive company information, HR processes, and IT systems; the announcement names TeraRecon's Intuition product and Eureka Clinical AI platform.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; the certificate was not read (a certificate PDF is hosted on the same owning domain). Applicant name variants (TeraRecon Inc. with punctuation/case variants) are bridged via the identical distinctive name. Exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for TeraRecon Cardiac.Chambers.MR (1.0.0); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K241312
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Cardiac chambers: left-ventricular myocardium and chamber, and right-ventricular chamber for the Cine-ax component; left-ventricular myocardium and chamber for the De-ax component.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-11-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
22Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K241312 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K241312: TeraRecon Cardiac.Chambers.MR (1.0.0)

    U.S. Food and Drug Administration - Published 2024-11-05 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. TeraRecon Cardiac.Chambers.MR (1.0.0) model card (K241312)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K241312

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. TeraRecon: ISO 27001:2022 Certification Announcement

    TeraRecon - Published 2023-05-30 - Accessed 2026-10-27

    Scope: security

Research history

  1. K241312 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K252084

AI4CMR v2.0

Ai4medimaging Medical Solutions S.A.

Authorized purpose: Cardiac MRI ventricular function and 2D phase-contrast flow quantification

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2026-02-11
FDA-cleared K241922

Myomics

Phantomics Inc.

Authorized purpose: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2025-02-28
FDA-cleared K232661

Myocardial Strain Software Application

Circle Cardiovascular Imaging

Authorized purpose: Myocardial Strain Software Application provides qualitative and quantitative evaluation of cardiovascular MR images, including two-dimensional displacement, velocity, strain, strain rate, time to peak, and torsion after a qualified user confirms the contours.

Modality
MRI
Anatomy
Heart; left ventricular myocardium and cardiovascular structures
Decision
2023-12-07
FDA-cleared K211611

QIR Suite

CASIS Cardiac Simulation & Imaging Software

Authorized purpose: View, post-process, and quantitatively evaluate cardiovascular MR images in DICOM format.

Modality
MRI
Anatomy
Cardiovascular/heart and aorta
Decision
2022-09-30

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history